Ropeginterferonα-2b治疗骨髓增殖性肿瘤的研究进展  

Research Progress of Ropeginterferonα-2b in Treatment of Myeloproliferative Neoplasm——Review

作　　者：屠玲榕 黄健[2] TU Ling-Rong;HUANG Jian(Department of Hematology,The Fourth Affiliated Hospital of Zhejiang University School of Medicine,Yiwu 322000,Zhejiang Province,China;Department of Hematology,The First Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310003,Zhejiang Province,China)

机构地区：[1]浙江大学医学院附属第四医院血液内科,浙江义乌322000 [2]浙江大学医学院附属第一医院血液科,浙江杭州310003

出　　处：《中国实验血液学杂志》2025年第1期306-310,共5页Journal of Experimental Hematology

基　　金：浙江省“领雁”研发攻关计划(2022C03137);浙江省基础公益研究项目(LGF21H080003);金华市科技公益重点项目(2020-3-011);浙江省医学会临床医学专项资金项目(2022ZYC-D09)。

摘　　要：Ropeginterferonα-2b是新上市的一种长效聚乙二醇脯氨酸α干扰素,是第一种专门批准用于治疗真性红细胞增多症的干扰素,临床试验和经验发现其可以诱导骨髓增殖性肿瘤患者血液学缓解,控制疾病相关症状,降低JAK2V617F基因突变负荷。与聚乙二醇干扰素α和羟基脲相比,其药物不良反应发生率和严重程度较低,且给药间隔时间更长,部分低危真性红细胞增多症和骨髓纤维化患者也能从中获益。本文就Ropeginterferonα-2b在骨髓增殖性肿瘤中的最新研究进展作一综述。Ropeginterferonα-2b(Ropeg),a novel,long-acting pegylated prolene alpha interferon,is the first interferon specifically approved for the treatment of patients with polycythemia vera(PV),and has been found in clinical trials and experience to induce hematologic remission,control disease-related symptoms,and reduce JAK2V617F allelic burden in patients with myeloproliferative neoplasms(MPNs).It has a lower incidence and severity of adverse drug reactions than pegylated interferon alpha and hydroxyurea and a longer dosing interval.Some patients with low-risk PV and myelofibrosis can benefit from it.This article reviews the latest progress of Ropeg in MPN.

关 键 词：骨髓增殖性肿瘤 Ropeginterferonα-2b Α干扰素 治疗 

分 类 号：R733.3[医药卫生—肿瘤]